Product Description
Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6114852/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Chile | Colombia | Denmark | Dominican Republic | Finland | Germany | Greece | Hong Kong | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | New Zealand | Pakistan | Peru | Portugal | Spain | Sweden | Switzerland | Taiwan | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/25/2025 |
News Article |
Randy Johnston Receives Lifetime Achievement Award from ALM, Law.com |
|
06/24/2024 |
News Article |
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US |
|
12/06/2023 |
News Article |
Woburn Dentistry Offers Sedation Dentistry to Help Patients Overcome "Dental Anxiety" |
|
10/13/2023 |
News Article |
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance |